Structure-based design of anti-infectives

Annals of the New York Academy of Sciences

Volumn 1213, Issue 1, 2010, Pages 20-45

  Agarwal, Anil K ^a   Fishwick, Colin W G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antibacterials; Antimalarials; Antivirals; de novo; Drugs; Structure based drug design; Virtual screening

Indexed keywords

AMPRENAVIR; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; ATAZANAVIR; CAPRAVIRINE; CEFTOBIPROLE; DARUNAVIR; DIHYDROFOLATE REDUCTASE INHIBITOR; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; IDX 899; INDINAVIR; INTEGRASE INHIBITOR; LERSIVIRINE; LOPINAVIR; MOZENAVIR; NELFINAVIR; OSELTAMIVIR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEINASE INHIBITOR; PSEUDOMONIC ACID; RDEA 806; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANAMIVIR;

ARTICLE; BACTERIAL INFECTION; DRUG DESIGN; DRUG STRUCTURE; HUMAN; MYCOSIS; NONHUMAN; PARASITOSIS; PROTOZOAL INFECTION; VIRUS INFECTION;

FUNGI; PROTOZOA;

EID: 78650383453     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05859.x     Document Type: Article

References (128)

1. WHO. 2008. The global burden of disease: 2004 update.
2. Binder, S., A.M. Levitt, J.J. Sacks & J.M. Hughes 1999. Emerging infectious diseases: public health issues for the 21st century. Science 284: 1311-1313.
3. Schmidt, F.R. 2004. The challenge of multidrug resistance: actual strategies in the development of novel antibacterials. Appl. Microbiol. Biotechnol. 63: 335-343.
4. Bradley, J.S., R. Guidos, S. Baragona, et al. 2007. Anti-infective research and development-problems, challenges, and solutions. Lancet Infect. Dis. 7: 68-78.
5. Jacobs, M.R. 2007. Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbiol. 2: 591-600.
6. Moro, S., M. Bacilieri & F. Deflorian 2007. Combining ligand-based and structure-based drug design in the virtual screening arena. Expert Opin. Drug Discov. 2: 37-49.
7. Tufts Centre for the Study of Drug Development, CSDD.
8. Golebiowski, A., S.R. Klopfenstein & D.E. Portlock 2001. Lead compounds discovered from libraries. Curr. Opin. Chem. Biol. 5: 273-284.
9. Golebiowski, A., S.R. Klopfenstein & D.E. Portlock 2003. Lead compounds discovered from libraries: part 2. Curr. Opin. Chem. Biol. 7: 308-325.
10. Dorsey, B.D., R.B. Levin, S.L. McDaniel, et al. 1994. L-735, 524-the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37: 3443-3451.
11. Erickson, J., D.J. Neidhart, J. Vandrie, et al. 1990. Design, activity and 2.8 a crystal-structure of a C2 symmetrical inhibitor complexed to HIV-1 protease. Science 249: 527-533.
12. Roberts, N.A., J.A. Martin, D. Kinchington, et al. 1990. Rational design of peptide-based HIV proteinase-inhibitors. Science 248: 358-361.
13. Kaldor, S.W., V.J. Kalish, J.F. Davies, et al. 1997. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40: 3979-3985.
14. Varghese, J.N. 1999. Development of neuraminidase inhibitors as anti-influenza virus drugs. Drug Dev. Res. 46: 176-196.
15. Blundell, T.L., H. Jhoti & C. Abell 2002. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1: 45-54.
16. Charifson, P.S., J.J. Corkery, M.A. Murcko & W.P. Walters 1999. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 42: 5100-5109.
17. Ghosh, S., A.H. Nie, J. An & Z.W. Huang 2006. Structure-based virtual screening of chemical libraries for drug discovery. Curr. Opin. Chem. Biol. 10: 194-202.
18. Jain, A.N. 2004. Virtual screening in lead discovery and optimization. Curr. Opin. Drug Discov. Dev. 7: 396-403.
19. Morris, G.M., D.S. Goodsell, R.S. Halliday, et al. 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19: 1639-1662.
20. Pavani, P., D.S. Mangala, J. Murthy & P.A. Babu 2008. Protein-ligand interaction studies on 2, 4, 6-trisubstituted triazine derivatives as anti-malarial DHFR agents using AutoDock. Res. J. Biotechnol. 3: 18-23.
21. Ewing, T.J.A., S. Makino, A.G. Skillman & I.D. Kuntz 2001. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des. 15: 411-428.
22. Moustakas, D.T., P.T. Lang, S. Pegg, et al. 2006. Development and validation of a modular, extensible docking program: DOCK 5. J. Comput. Aided Mol. Des. 20: 601-619.
23. Zsoldos, Z., D. Reid, A. Simon, et al. 2006. eHITS: an innovative approach to the docking and scoring function problems. Curr. Protein Peptide Sci. 7: 421-435.
24. Steffen, A., A. Kamper & T. Lengauer 2006. Flexible docking of ligands into synthetic receptors using a two-sided incremental construction algorithm. J. Chem. Inf. Model. 46: 1695-1703.
25. Schulz-Gasch, T. & M. Stahl 2003. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J. Mol. Model. 9: 47-57.
26. Friesner, R.A., J.L. Banks, R.B. Murphy, et al. 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47: 1739-1749.
27. Halgren, T.A., R.B. Murphy, R.A. Friesner, et al. 2004. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47: 1750-1759.
28. Jones, G., P. Willett, R.C. Glen, et al. 1997. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267: 727-748.
29. Montes, M., M.A. Miteva & B.O. Villoutreix 2007. Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections. Proteins-Struct. Funct. Bioinformatics 68: 712-725.
30. Barreiro, G., J.T. Kim, C.R.W. Guimares, et al. 2007. From docking false-positive to active Anti-HIV agent. J. Med. Chem. 50: 5324-5329.
31. Bohm, H.J. 1992. Ludi-rule-based automatic design of new substituents for enzyme-inhibitor leads. J. Comput. Aided Mol. Des. 6: 593-606.
32. Bohm, H.J. 1992. The computer-program ludi-a new method for the de novo design of enzyme-inhibitors. J. Comput. Aided Mol. Des. 6: 61-78.
33. Gillet, V.J., W. Newell, P. Mata, et al. 1994. Sprout-recent developments in the de-novo design of molecules. J. Chem. Inf. Comput. Sci. 34: 207-217.
34. Law, J.M.S., D.Y.K. Fung, Z. Zsoldos, et al. 2003. Validation of the SPROUT de novo design program. J. Mol. Struct.-Theochem 666: 651-657.
35. Kohring, K., J. Wiesner, M. Altenkamper, et al. 2008. Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials. ChemMedChem 3: 1217-1231.
36. Chhibber, M., G. Kurnara, P. Parasuraman, et al. 2006. Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Biorg. Med. Chem. 14: 8086-8098.
37. Li, R.S., X.W. Chen, B.Q. Gong, et al. 1996. Structure-based design of parasitic protease inhibitors. Biorg. Med. Chem. 4: 1421-1427.
38. Rastelli, G., S. Pacchioni, W. Sirawaraporn, et al. 2003. Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors. J. Med. Chem. 46: 2834-2845.
39. Chen, I.J., N. Neamati, M.C. Nicklaus, et al. 2000. Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. Biorg. Med. Chem. 8: 2385-2398.
40. Chen, C.S., C.T. Chiou, G.S. Chen, et al. 2009. Structure-based discovery of triphenylmethane derivatives as inhibitors of Hepatitis C virus helicase. J. Med. Chem. 52: 2716-2723.
41. Turk, S., A. Kovac, A. Boniface, et al. 2009. Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. Biorg. Med. Chem. 17: 1884-1889.
42. Luksch, T., N.S. Chan, S. Brass, et al. 2008. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors. ChemMedChem 3: 1323-1336.
43. Brvar, M., A. Perdih, M. Oblak, et al. 2010. In silico discovery of 2-amino-4-(2, 4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B. Bioorg. Med. Chem. Lett. 20: 958-962.
44. Bustanji, Y., I.M. Al-Masri, A. Qasem, et al. 2009. In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation. Chem. Biol. Drug Des. 74: 258-265.
45. Li, H.L., J. Huang, L.L. Chen, et al. 2009. Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. J. Med. Chem. 52: 4936-4940.
46. Nichols, S.E., R.A. Domaoal, V.V. Thakur, et al. 2009. Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures. J. Chem. Inf. Model. 49: 1272-1279.
47. Glenn, M.R., S.Y. Chang, O. Hucke, et al. 2005. Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angew. Chemie-Int. Ed. 44: 4903-4906.
48. Desai, P.V., A. Patny, J. Gut, et al. 2006. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J. Med. Chem. 49: 1576-1584.
49. Desai, P.V., A. Patny, Y. Sabnis, et al. 2004. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J. Med. Chem. 47: 6609-6615.
50. Kellenberger, E., J.Y. Springael, M. Parmentier, et al. 2007. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J. Med. Chem. 50: 1294-1303.
51. Jorgensen, W.L. 2009. Efficient drug lead discovery and optimization. Acc. Chem. Res. 42: 724-733.
52. Oblak, M., S.G. Grdadolnik, M. Kotnik, et al. 2005. In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Bioorg. Med. Chem. Lett. 15: 5207-5210.
53. D'Cruz, O.J. & F.M. Uckun 2006. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr. Hiv Res. 4: 329-345.
54. Heikkila, T., C. Ramsey, M. Davies, et al. 2007. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J. Med. Chem. 50: 186-191.
55. Agarwal, A.K., A.P. Johnson & C.W.G. Fishwick 2008. Synthesis of de novo designed small-molecule inhibitors of bacterial RNA polymerase. Tetrahedron 64: 10049-10054.
56. Besong, G.E., J.M. Bostock, W. Stubbings, et al. 2005. A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli. Angew. Chem. Int. Ed. 44: 6403-6406.
57. Horton, J.R., J.M. Bostock, I. Chopra, et al. 2003. Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme Mur D. Bioorg. Med. Chem. Lett. 13: 1557-1560.
58. Baum, E.Z., S.M. Crespo-Carbone, A. Klinger, et al. 2007. A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli. Antimicrob. Agents Chemother. 51: 4420-4426.
59. Clark, D.E. 2008. What has virtual screening ever done for drug discovery? Expert Opin. Drug Discov. 3: 841-851.
60. Becker, K., Y. Hu & N. Biller-Andorno 2006. Infectious diseases-a global challenge. Int. J. Med. Microbiol. 296: 179-185.
61. Sahu, N.K., S. Sahu & D.V. Kohli 2008. Novel molecular targets for antimalarial drug development. Chem. Biol. Drug Des. 71: 287-297.
62. Wells, T.N.C., P.L. Alonso & W.E. Gutteridge 2009. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 8: 879-891.
63. Olliaro, P. & T.N.C. Wells 2009. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther. 85: 584-595.
64. Rathore, D., T.F. McCutchan, M. Sullivan & S. Kumar 2005. Antimalarial drugs: current status and new developments. Expert Opin. Invest. Drugs 14: 871-883.
65. Phillips, M.A. & P.K. Rathod 2010. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect. Disord. - Drug Targets 10: 226-239.
66. Heikkila, T., S. Thirumalairajan, M. Davies, et al. 2006. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg. Med. Chem. Lett. 16: 88-92.
67. Li, H.L., C.L. Li, C.S. Gui, et al. 2004. GAsDock: a new approach for rapid flexible docking based on an improved multi-population genetic algorithm. Bioorg. Med. Chem. Lett. 14: 4671-4676.
68. Boss, C., O. Corminboeuf, C. Grisostomi & T. Weller 2006. Inhibitors of aspartic proteases-potential antimalarial agents. Expert Opin. Ther. Patents 16: 295-317.
69. Bjelic, S., M. Nervall, H. Gutierrez-de-Teran, et al. 2007. Computational inhibitor design against malaria plasmepsins. Cell. Mol. Life Sci. 64: 2285-2305.
70. Adane, L., D.S. Patel & P.V. Bharatam 2010. Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition. Chem. Biol. Drug Des. 75: 115-126.
71. UNAIDS/WHO. 2009. AIDS Epidemic Update.
72. Greene, W.C., Z. Debyser, Y. Ikeda, et al. 2008. Novel targets for HIV therapy. Antivir. Res. 80: 251-265.
73. Mastrolorenzo, A., S. Rusconi, A. Scozzafava & C.T. Supuran 2006. Inhibitors of HIV-1 protease: 10 years after. Expert Opin. Ther. Patents 16: 1067-1091.
74. Tung, R.D., D.J. Livingston, B.G. Rao, et al. 2002. Design and synthesis of amprenavir, a novel HIV protease inhibitor. Infect. Dis. Therapy 25: 101-118.
75. Ghosh, A.K., B.D. Chapsal, I.T. Weber & H. Mitsuya 2008. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res. 41: 78-86.
76. Ghosh, A.K., S. Kulkarni, D.D. Anderson, et al. 2009. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. J. Med. Chem. 52: 7689-7705.
77. Wlodawer, A. 2002. Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 53: 595-614.
78. de Bethune, M.P. 2010. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antivir. Res. 85: 75-90.
79. McGaughey, G.B., R.P. Sheridan, C.I. Bayly, et al. 2007. Comparison of topological, shape, and docking methods in virtual screening. J. Chem. Inf. Model. 47: 1504-1519.
80. Jones, L.H., G. Allan, O. Barba, et al. 2009. Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. J. Med. Chem. 52: 1219-1223.
81. Savarino, A. 2006. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin. Invest. Drugs 15: 1507-1522.
82. Mugnaini, C., S. Rajamaki, C. Tintori, et al. 2007. Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies. Bioorg. Med. Chem. Lett. 17: 5370-5373.
83. Perez-Nueno, V.I., S. Pettersson, D.W. Ritchie, et al. 2009. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening. J. Chem. Inf. Model. 49: 810-823.
84. Perez-Nueno, V.I., D.W. Ritchie, O. Rabal, et al. 2008. Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking. J. Chem. Inf. Model. 48: 509-533.
85. Liang, X.Y. 2008. CXCR4, inhibitors and mechanisms of action. Chem. Biol. Drug Des. 72: 97-110.
86. Zhan, W.Q., Z.X. Liang, A.Z. Zhu, et al. 2007. Discovery of small molecule CXCR4 antagonists. J. Med. Chem. 50: 5655-5664.
87. Palani, A., S. Shapiro, J.W. Clader, et al. 2001. Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl-1'-[(2, 4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1, 4'-bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J. Med. Chem. 44: 3339-3342.
88. Palani, A. & J.R. Tagat 2006. Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists. J. Med. Chem. 49: 2851-2857.
89. Dorr, P. & M. Perros 2008. CCR5 inhibitors in HIV-1 therapy. Expert Opin. Drug Discov. 3: 1345-1361.
90. Vonitzstein, M., W.Y. Wu, G.B. Kok, et al. 1993. Rational design of potent sialidase-based inhibitors of influenza-virus replication. Nature 363: 418-423.
91. Kim, C.U., W. Lew, M.A. Williams, et al. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119: 681-690.
92. Tomlinson, S.M., R.D. Malmstrom & S.J. Watowich 2009. New approaches to structure-based discovery of dengue protease inhibitors. Infect. Disord. - Drug Targets 9: 327-343.
93. Stevens, A.J., M.E. Gahan, S. Mahalingam & P.A. Keller 2009. The medicinal chemistry of dengue fever. J. Med. Chem. 52: 7911-7926.
94. Zhou, Z.G., M. Khaliq, J.E. Suk, et al. 2008. Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem. Biol. 3: 765-775.
95. Podvinec, M., S.P. Lim, T. Schmidt, et al. 2010. Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid. J. Med. Chem. 53: 1483-1495.
96. Yin, Z., Y.L. Chen, R.R. Kondreddi, et al. 2009. N-Sulfonylanthranilic acid derivatives as allosteric inhibitors of dengue viral RNA-dependent RNA polymerase. J. Med. Chem. 52: 7934-7937.
97. Manns, M.P., G.R. Foster, J.K. Rockstroh, et al. 2007. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov. 6: 991-1000.
98. Vandyck, K., M.D. Cummings, O. Nyanguile, et al. 2009. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase. J. Med. Chem. 52: 4099-4102.
99. Barrett, C.T. & J.F. Barrett 2003. Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr. Opin. Biotechnol. 14: 621-626.
100. Projan, S.J. & D.M. Shlaes 2004. Antibacterial drug discovery: is it all downhill from here? Clin. Microbiol. Infect. 10: 18-22.
101. Alekshun, M.N. 2005. New advances in antibiotic development and discovery. Expert Opin. Invest. Drugs 14: 117-134.
102. Overbye, K.M. & J.F. Barrett 2005. Antibiotics: where did we go wrong. Drug Discov. Today 10: 45-52.
103. Theuretzbacher, U. 2009. Future antibiotics scenarios: is the tide starting to turn? Int. J. Antimicrob. Agents 34: 15-20.
104. Thomson, C.J., E. Power, H. Ruebsamen-Waigmann & H. Labischinski 2004. Antibacterial research and development in the 21(st) century-an industry perspective of the challenges. Curr. Opin. Microbiol. 7: 445-450.
105. Payne, D.J., M.N. Gwynn, D.J. Holmes & D.L. Pompliano 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6: 29-40.
106. Simmons, K.J., I. Chopra & C.W.G. Fishwick 2010. Structure-based discovery of antibacterial drugs. Nat. Rev. Microbiol. 8: 501-510.
107. Drlica, K. & X.L. Zhao 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61: 377-+.
108. Ostrov, D.A., J.A.H. Prada, P.E. Corsino, et al. 2007. Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening. Antimicrob. Agents Chemother. 51: 3688-3698.
109. Beyer, D., H.P. Kroll, R. Endermann, et al. 2004. New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity. Antimicrob. Agents Chemother. 48: 525-532.
110. Ochsner, U.A., X. Sun, T. Jarvis, et al. 2007. Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents. Expert Opin. Invest. Drugs 16: 573-593.
111. Brown, M.J.B., L.M. Mensah, M.L. Doyle, et al. 2000. Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry 39: 6003-6011.
112. Moro, W.B., Z.R. Yang, T.A. Kane, et al. 2009. Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs). Bioorg. Med. Chem. Lett. 19: 2001-2005.
113. Lipinski, C.A., F. Lombardo, B.W. Dominy & P.J. Feeney 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23: 3-25.
114. Dessalew, N. & P.V. Bharatam 2007. Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening. Biophys. Chem. 128: 165-175.
115. Pakodi, F., O.M.E. Abdel-Salam, A. Debreceni & G. Mozsik 2000. Helicobacter pylori: one bacterium and a broad spectrum of human disease! An overview. J. Physiol.-Paris 94: 139-152.
116. He, L.Y., L. Zhang, X.F. Liu, et al. 2009. Discovering potent inhibitors against the beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ) of Helicobacter pylori: structure-based design, synthesis, bioassay, and crystal structure determination. J. Med. Chem. 52: 2465-2481.
117. Chen, G., S.X. Zheng, X.M. Luo, et al. 2005. Focused combinatorial library design based on structural diversity, drug likeness and binding affinity score. J. Comb. Chem. 7: 398-406.
118. Lu, H. & P.J. Tonge 2008. Inhibitors of Fabl, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc. Chem. Res. 41: 11-20.
119. Miller, W.H., M.A. Seefeld, K.A. Newlander, et al. 2002. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 45: 3246-3256.
120. Payne, D.J., W.H. Miller, V. Berry, et al. 2002. Discovery of a novel and potent class of fabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46: 3118-3124.
121. Karlowsky, J.A., N.M. Laing, T. Baudry, et al. 2007. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 51: 1580-1581.
122. Park, H.S., Y.M. Yoon, S.J. Jung, et al. 2007. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J. Antimicrob. Chemother. 60: 568-574.
123. Stamper, G.F., K.L. Longenecker, E.H. Fry, et al. 2006. Structure-based optimization of MurF inhibitors. Chem. Biol. Drug Des. 67: 58-65.
124. Page, M.G.P. 2006. Anti-MRSA beta-lactams in development. Curr. Opin. Pharmacol. 6: 480-485.
125. Page, M.G.P. 2007. Ceftobiprole-a case study. Expert Opin. Drug Discov. 2: 115-129.
126. Cornaglia, G. & G.M. Rossolini 2009. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin. Microbiol. Infect. 15: 218-223.
127. Miguet, L., A. Zervosen, T. Gerards, et al. 2009. Discovery of new inhibitors of resistant streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening. J. Med. Chem. 52: 5926-5936.
128. Hawser, S., S. Lociuro & K. Islam 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 71: 941-948.